AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 FEB 14 - (NewsRx.com & NewsRx.net) --
- by Michelle Marble, staff medical writer -- According to a study from Sweden, the spontaneous immunity found in some chronic lymphocytic leukemia (CLL) patients could be harnessed in a vaccine.
"This study analyzed a naturally-occurring specific cellular immunity against tumor cells in chronic lymphocytic leukemia (CLL) patients," stated M.R. Rezvany and colleagues, Karolinska Hospital. "Five out of eight patients had blood T lymphocytes able to recognize spontaneously and specifically the autologous tumor B cells (proliferation assay)."
Rezvany et al. published the results of their study in the British Journal of Hematology ("Autologous T lymphocytes may specifically recognize leukemic B cells in patients with chronic lymphocytic leukemia," Brit J Hematol, 2000;111(2):608-617).
"In these five patients, detection of cytokines by real-time reverse transcription polymerase chain reaction (RT-PCR) revealed that granulocyte-macrophage colony-stimulating factor (GM-CSF) was the most abundant cytokine gene expressed by the T cells that recognized the autologous tumor B cells," continued the researchers. "Other activated cytokine genes were gamma-interferon (IFN), interleukin (IL)-2 and tumor necrosis factor (TNF)-alpha, but not IL-4."
According to the authors, this type of cytokine profile suggested a type 1 anti-B-CLL T-cell response. They found that CD80 and CD54 cells were relatively downregulated on the native tumor B cells as compared with control normal B cells. Their data ...